Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
Many nations are pursuing the rollout of SARS-CoV-2 vaccines as an exit strategy from
unprecedented COVID-19-related restrictions. However, the success of this strategy relies …
unprecedented COVID-19-related restrictions. However, the success of this strategy relies …
Cancer vaccines, adjuvants, and delivery systems
SJ Paston, VA Brentville, P Symonds… - Frontiers in …, 2021 - frontiersin.org
Vaccination was first pioneered in the 18th century by Edward Jenner and eventually led to
the development of the smallpox vaccine and subsequently the eradication of smallpox. The …
the development of the smallpox vaccine and subsequently the eradication of smallpox. The …
[HTML][HTML] ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
N Van Doremalen, T Lambe, A Spencer… - Nature, 2020 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December
2019 1, 2 and is responsible for the coronavirus disease 2019 (COVID-19) pandemic 3 …
2019 1, 2 and is responsible for the coronavirus disease 2019 (COVID-19) pandemic 3 …
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines
L Coughlan - Frontiers in immunology, 2020 - frontiersin.org
Adenoviral vectors are a safe and potently immunogenic vaccine delivery platform. Non-
replicating Ad vectors possess several attributes which make them attractive vaccines for …
replicating Ad vectors possess several attributes which make them attractive vaccines for …
[HTML][HTML] New viral vectors for infectious diseases and cancer
E Sasso, AM D'Alise, N Zambrano, E Scarselli… - Seminars in …, 2020 - Elsevier
Since the discovery in 1796 by Edward Jenner of vaccinia virus as a way to prevent and
finally eradicate smallpox, the concept of using a virus to fight another virus has evolved into …
finally eradicate smallpox, the concept of using a virus to fight another virus has evolved into …
Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development
During the COVID-19 pandemic in a modern era, there is a global consensus on the need
for the rapid development of a vaccine against SARS-CoV-2 for effective and sustainable …
for the rapid development of a vaccine against SARS-CoV-2 for effective and sustainable …
Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials
Immunogenicity of T cell-inducing vaccines, such as viral vectors or DNA vaccines and
Bacillus Calmette-Guérin (BCG), are frequently assessed by cytokine-based approaches …
Bacillus Calmette-Guérin (BCG), are frequently assessed by cytokine-based approaches …
Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors
Interactions between B cells and CD4+ T follicular helper (Tfh) cells are key determinants of
humoral responses. Using samples from clinical trials performed with the malaria vaccine …
humoral responses. Using samples from clinical trials performed with the malaria vaccine …
Recent advances in the development of adenovirus-vectored vaccines for parasitic infections
Vaccines against parasites have lagged centuries behind those against viral and bacterial
infections, despite the devastating morbidity and widespread effects of parasitic diseases …
infections, despite the devastating morbidity and widespread effects of parasitic diseases …